PDS Biotechnology Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 28, 2024. This is an annual report, not a standalone fourth-quarter report. PDS Biotechnology is a clinical-stage immunotherapy company with no approved products and no product revenue.
Business context
The company is developing Versamune-based cancer immunotherapies, including PDS0101, and PDS01ADC, a tumor-targeting IL-12 immunocytokine. Its Infectimune platform includes PDS0202, an investigational universal influenza vaccine. Most programs remain in clinical or preclinical development; PDS0101 and PDS01ADC are central to the company’s development plans.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $27.8 million | $29.4 million |
| General and administrative expense | $15.3 million | $12.2 million |
| Total operating expenses | $43.0 million | $41.7 million |
| Net loss | $42.9 million | $40.9 million |
| Net loss per share, basic and diluted | $1.39 | $1.43 |
| Cash used in operating activities | $33.6 million | $25.7 million |
| Cash and cash equivalents at year-end | $56.6 million | $73.8 million |
There are no meaningful revenue or profit margins to assess because the company has no product sales and reported operating losses. R&D expense declined 6%, mainly because FY2022 included a $10.0 million PDS01ADC license cost; clinical and personnel costs increased in FY2023. G&A increased 25%, reflecting higher personnel and professional fees. Net interest expense was $1.3 million, versus $0.4 million in FY2022: higher interest expense on the Horizon loan was partly offset by increased interest income.
At December 31, 2023, total current assets were $59.1 million and current liabilities were $13.6 million. Total liabilities were $33.3 million, including notes payable reported at a net carrying amount of approximately $23.7 million and financing lease obligations. Stockholders’ equity was $26.1 million, down from $44.0 million; accumulated deficit reached $144.5 million. Cash declined $17.3 million during the year. Cash used in investing activities was primarily for Princeton laboratory equipment; the filing does not provide a clear amount in the summarized cash-flow discussion.
Material changes, funding and debt
- Cash used in operations increased $7.9 million year over year, while net loss increased $2.1 million.
- The company raised $16.1 million net through its at-the-market (ATM) stock program in 2023, issuing 2.64 million shares. After year-end, it sold a further 3.43 million shares for $19.5 million net in the first quarter of 2024.
- The Horizon venture loan provided $25.0 million of principal in 2022, with $24.6 million net proceeds. The additional potential $10.0 million in Loans E and F expired unadvanced. Principal payments begin October 2024; the loans mature 48 months after funding. Interest floats at prime plus 5.75%, subject to a 4.00% floor.
- The loan is secured by company assets, excluding intellectual property, and includes minimum-cash requirements and other restrictive covenants. The company reported compliance with covenants at year-end; lenders may accelerate the debt if specified defaults occur, including failure to maintain required cash balances.
- The Merck KGaA license for PDS01ADC includes up to $11 million in development and first-commercial-sale milestones, up to $105 million in sales milestones, and a 10% royalty on net sales, subject to contractual terms.
Clinical progress, outlook and key risks
- NCI triple-combination study: In November 2023, the company reported interim results for PDS0101, PDS01ADC and an investigational checkpoint inhibitor in HPV16-positive cancers. Reported results included approximately 20 months median overall survival in the ICI-resistant group, a 72% 12-month survival rate, and 75% of ICI-naive patients alive at 36 months. The study is closed to enrollment and long-term follow-up continues. These are interim results from a clinical study, not comparative evidence of efficacy; the filing cites historical comparators.
- VERSATILE-002: This Phase 2 study evaluates PDS0101 plus pembrolizumab in recurrent or metastatic HPV16-positive head and neck cancer. Interim, investigator-assessed results included 27% confirmed response in the ICI-naive cohort and a 56% 12-month survival rate in the ICI-refractory cohort. Enrollment was complete in the ICI-naive arm; the filing describes FDA feedback on an amended IND and a Phase 3 program plan, but no pivotal trial had begun. FDA Fast Track designation was granted in 2022. The company states there are no control or comparative studies establishing superiority over checkpoint inhibitor treatment alone.
- Other programs: IMMUNOCERV reported early ctHPV-DNA clearance results for PDS0101 plus chemoradiotherapy versus standard chemoradiotherapy. PDS01ADC plus docetaxel produced PSA decreases in reported patients, with one Grade 4 neutropenia. PDS0202 has shown preclinical influenza neutralization and protection in animals; the company was evaluating next steps and funding. PDS0103 remained in manufacturing and clinical scale-up, with an IND submission targeted for 2024, subject to resource allocation.
- Funding outlook: Management expects continued losses and cash outflows and says additional capital will be needed for development and operations. The company plans to pursue equity or debt financing, collaborations, licensing and potentially government funding, but availability and terms are uncertain. Equity financing may dilute shareholders; debt may impose repayment obligations and restrictions.
- Going concern: Management concluded that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months from issuance of the financial statements, citing recurring losses, negative operating cash flow, funding uncertainty and debt cash covenants. The auditor issued an unqualified opinion on the financial statements while highlighting the going-concern uncertainty.
- Key business risks include clinical-trial failure or delay, dependence on third-party manufacturers and research organizations, regulatory approval uncertainty, competition, intellectual-property challenges, future financing needs, and potential dilution. The company relies on external manufacturers and has no commercial sales, marketing or distribution infrastructure.
Important facts for investors to verify
- Current cash, post-year-end ATM proceeds, remaining ATM capacity and the company’s updated cash runway and financing plans.
- Horizon loan principal outstanding, interest rate, minimum-cash covenant levels, and the effect of principal amortization beginning in October 2024.
- Final, independently reviewed clinical results and full safety data for the NCI triple-combination study and VERSATILE-002, including cohort sizes, follow-up and endpoint definitions.
- Whether FDA feedback supports a registrational path, and the timing, design, cost and funding source for any pivotal PDS0101 trial.
- Manufacturing readiness, third-party supply capacity, license milestones and royalties, and the potential dilution from further equity issuance.